Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TASO-001 + Aldesleukin in Advanced Solid Tumors
NCT04862767Phase 1Completed
- Sponsor
- Autotelic Bio
- Start
- Mar 2021
- Primary completion
- Aug 2023
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of trabedersen in solid tumor, sponsored by Autotelic Bio. Primary endpoint: Maximum Tolerated Dose (Incidence of Dose Limiting Toxicity) at 4 weeks. Started Mar 2021; status: completed.
02
Drugs
trabedersen
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04862767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04862767.